Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Dallas, Texas

11 studies are recruiting for non-small cell lung cancer (nsclc) in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT - Dallas, Dallas, Texas

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

2. Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

   This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active dru…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baylor Charles A. Sammons Cancer Center, Dallas, Texas

   Locations

   74 in total

   Run by

   Genmab

   See if you can join NCT07288177 on ClinicalTrials.gov

3. A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

   Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Southwestern Medical Center at Dallas, Dallas, Texas

   Locations

   17 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07140016 on ClinicalTrials.gov

4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #111, Dallas, Texas

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

5. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mary Crowley Cancer Research, Dallas, Texas

   Locations

   55 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06128551 on ClinicalTrials.gov

6. A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

   The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 0046, Dallas, Texas

   Locations

   17 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06476808 on ClinicalTrials.gov

7. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

   IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants wi…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   NEXT Texas LLC - Dallas, Dallas, Texas

   Locations

   11 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07540572 on ClinicalTrials.gov

8. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

   This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Southwestern Simmons Cancer Center, Dallas, Texas

   Locations

   38 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06026410 on ClinicalTrials.gov

9. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

   This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas

   Locations

   17 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06040541 on ClinicalTrials.gov

10. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mary Crowley Cancer Research, Dallas, Texas

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

11. Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

    The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robo…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Locations

    2 in total

    Run by

    Integro Theranostics

    See if you can join NCT07276789 on ClinicalTrials.gov